Bill
S 527
The bill requires the FTC to study PBMs and intermediaries in the drug supply chain and report on practices affecting prices and competition.
The Prescription Pricing for the People Act of 2025 (S.527) mandates the Federal Trade Commission (FTC) to investigate the role of intermediaries, particularly pharmacy benefit managers (PBMs), in the pharmaceutical supply chain. The FTC is required to submit a report to Congress within one year, examining practices such as whether PBMs charge payers more than they reimburse pharmacies, steer patients to affiliated pharmacies, misuse proprietary data, or design formularies favoring higher-cost drugs. The bill also seeks to identify legal or regulatory obstacles affecting antitrust and consumer protection enforcement in the pharmaceutical supply chain. (congress.gov)
This legislation aims to enhance transparency and competition within the pharmaceutical supply chain, potentially leading to lower prescription drug prices and improved patient access to medications. By scrutinizing PBMs' practices, the bill seeks to address concerns that these intermediaries may contribute to inflated drug costs and limited consumer choice. (procarerx.com)
Industry Resistance: Pharmaceutical companies and PBMs may oppose the bill, arguing that increased regulation could disrupt existing business models and hinder innovation.
Implementation Challenges: The effectiveness of the FTC's study and subsequent recommendations may be limited by the complexity of the pharmaceutical supply chain and potential legal challenges.
Impact on Drug Prices: While the bill aims to lower drug prices, there is uncertainty about whether the proposed measures will lead to significant cost reductions for consumers.
Regulatory Overreach: Critics may view the bill as an overextension of government authority into private business practices, raising concerns about free market principles.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
